[Iatrogenic dermatoses caused by beta-blocking drugs].
D000070:Acebutolol / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000526:Alprenolol / Q000009:adverse effects; D001262:Atenolol / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D004983:Ethanolamines / Q000009:adverse effects; D005734:Gangrene / Q000139:chemically induced; D006801:Humans; D007049:Iatrogenic Disease; D007741:Labetalol / Q000009:adverse effects; D008790:Metoprolol / Q000009:adverse effects; D009248:Nadolol; D010096:Oxprenolol / Q000009:adverse effects; D050198:Phenoxypropanolamines; D010869:Pindolol / Q000009:adverse effects; D011217:Practolol / Q000009:adverse effects; D011412:Propanolamines / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D011928:Raynaud Disease / Q000139:chemically induced; D013015:Sotalol / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D050198:Phenoxypropanolamines; D011412:Propanolamines; D009248:Nadolol; D001262:Atenolol; D010096:Oxprenolol; D000070:Acebutolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; C009976:moprolol; D010869:Pindolol; C100250:nifenalol; D008790:Metoprolol; D007741:Labetalol; D011217:Practolol
Le dermatosi iatrogene da farmaci beta-bloccanti.